Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation. To date several biomarkers are used for the diagnosis of IBD, such as CRP (blood) and Fecal (stool), which are limited due to low specificity and low sensitivity for diagnosing IBD. Therefore, colonoscopy, an invasive, time consuming and costly procedure, remains the gold standard method for diagnosis and monitoring of IBD.
Our invention suggests a new non-invasive and specific IBD diagnostic tool using clock gene and protein expression detected in simple blood samples.
The proposed invention is a diagnostic tool for IBD and other systemic diseases, which measures the expression of the main circadian clock genes/proteins. These genes/proteins can be measured systemically and therefore hold the potential of being diagnosed and monitored by a simple blood sample.
A specific, fast and non-invasive simple blood test, relying on systemic rather than local markers, with no side effects and complications
Diagnostic tool able to:
Monitor response to medical drug treatment
Follow up patients in remission (between flares), and possibility of intervention and preventive care
ELISA-based or gene-expression-based kits can be used at point of care
Can be applicable for all systemic diseases
The researcher’s overall goal is to develop diagnostic ELISA and/or gene expression kits with several clock protein/gene which can diagnose IBD as well as reflect disease state (remission/flare-ups), IBD severity and classification, and monitor the patient’s response to medical treatment. Such a tool can reduce the use of invasive tests along the diagnosed IBD patient’s life.
Develop ELISA as well as gene expression kits that combine several proteins/genes for reliable and specific detection (2 year research)
Provisional application in preparation